Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported Q1 2026 net product sales of $15.1 million, a 73% increase from the $8.8 million reported in Q1 2025. The company initiated a third institution-led clinical study by the University of Arizona Cancer Center to evaluate PEDMARK(®) in AYA and adult patients with head and neck and testicular cancers. Four abstracts evaluating PEDMARK(®) have been accepted for the upcoming 2026 ASCO Annual Meeting, highlighting growing clinical interest in the drug.
Key figures
- Eps
- 0.01
- Revenue
- 15108000
- Revenue Yoy
- 73%
- Cash position
- 40179000
- G and a expenses
- 3186000
- Selling and marketing expenses
- 11422000
- Selling and marketing expenses yoy
- 8200000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.